BioPorto A/S (THOXF)

USD 0.29

(0.0%)

Market Cap (In USD)

123.74 Million

Revenue (In USD)

30.95 Million

Net Income (In USD)

-56.32 Million

Avg. Volume

806.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.23-0.43451
PE
-
EPS
-
Beta Value
1.146
ISIN
DK0011048619
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Mr. Peter Moerch Eriksen B.B.A., BBA
Employee Count
-
Website
https://bioporto.com
Ipo Date
2019-12-13
Details
BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.